• Explore /
  • Poster
  • / Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C.

Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C.

Abstract Video & Slides Poster

Authors

null

Christian Grohé

Department of Pneumology, ELK Berlin, Berlin, Germany

Christian Grohé , Thomas Wehler , Tobias Dechow , Sven Henschke , Wolfgang Schuette , Ina Dittrich , Stefan Hammerschmidt , Harald Müller-Huesmann , Christian Schumann , Stefan Krüger , Judith Atz , Rolf Kaiser

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02392455

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9033)

DOI

10.1200/JCO.2021.39.15_suppl.9033

Abstract #

9033

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Christian Grohé

First Author: Christian Grohé

First Author: Patrick Walsh McGarrah

First Author: Wint Yan Aung